Info
Talk Summary:
We will review the clinical evaluation of cognitive impairment including the use of molecular imaging and its association with fluid biomarkers. Cases will be included to illustrate the diagnostic utility of biomarkers in the real world. We will touch on emerging molecular imaging and fluid biomarkers and their possible impact on the future of neurodegenerative disease evaluation.

Learning objectives:

– Understand the basic steps of a cognitive evaluation

– Explain the utility of molecular imaging and fluid biomarkers in the cognitive evaluation

– Describe the impact of molecular imaging on the treatment plan for cognitive disorders

– Consider the future landscape of the cognitive evaluation with emerging imaging and fluid biomarkers

Presenter Biography:
Dr. Christine J. Cliatt Brown is an Assistant Professor and Behavioral Neurologist at the University of Utah and a staff neurologist at the George E. Wahlen VA Medical Center in Salt Lake City. She graduated from the University of Colorado School of Medicine, completed her residency in neurology at the University of Utah, and completed her fellowship in Behavioral Neurology at Mayo Clinic in Rochester, MN. Dr. Cliatt Brown’s areas of interest are in early-onset and atypical presentations of dementia and Normal Pressure Hydrocephalus (NPH). She seeks to improve education on dementia diagnosis and management including use of emerging biomarkers.

Author
Christine Cliatt Brown
University of Utah